Up a level |
Number of items: 1.
Cebon, Jonathan S, Gore, Martin, Thompson, John F, Davis, Ian D, McArthur, Grant A, Walpole, Euan, Smithers, Mark, Cerundolo, Vincenzo, Dunbar, P Rod, MacGregor, Duncan et al (show 23 more authors)
(2020)
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8 (1).
e000410-.